.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02A_Antacids.A02AA02_MagnesiumOxide.MagnesiumOxide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02A_Antacids.A02AA02_MagnesiumOxide.MagnesiumOxide| name: | MagnesiumOxide |
| ATC code: | A02AA02 | route: | oral |
| n-compartments | 1 |
Magnesium oxide is an inorganic compound used primarily as a mineral supplement for the treatment and prevention of magnesium deficiency. It is also commonly used as an antacid for the relief of heartburn and indigestion, and as a laxative for constipation. Magnesium oxide is approved for over-the-counter use in many countries for these indications.
Estimated oral pharmacokinetic parameters for healthy adults; specific pharmacokinetic studies for magnesium oxide as a distinct entity are scarce as magnesium is an essential mineral and drug absorption is highly variable and incomplete. Most reports focus on magnesium bioavailability or serum levels following supplementation.
Kashihara, Y, et al., & Ieiri, I (2019). Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. European journal of clinical pharmacology 75(3) 351–361. DOI:10.1007/s00228-018-2568-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30382297
Hoy, SM, et al., & Wagstaff, AJ (2009). Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 69(1) 123–136. DOI:10.2165/00003495-200969010-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19192941
Schuette, SA, et al., & Janghorbani, M (1994). Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN. Journal of parenteral and enteral nutrition 18(5) 430–435. DOI:10.1177/0148607194018005430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7815675